Phase 4
Completed N=71
Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis
Facial Nerve Injuries · Facial Paresis Associated With Facial Nerve Dysfunction · Facial Asymmetry · Synkinesis
Source: ClinicalTrials.gov NCT03048383 ↗
Enrolled (actual)
71
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcomePrimary: Change in Synkinesis Assessment Questionnaire (SAQ) Scores — 45.9; 38.8; 51.3; 45.2 units on a scale
◆ Published Evidence
Established
21citations · ~3 / year
Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.
Summary
The purpose of this study is to compare the effectiveness of three commercially available botulinum toxin neuromodulators in the treatment of facial synkinesis using patient reported outcome measures.
Linked Publications
-
Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Synkinesis Assessment Questionnaire (SAQ) Scores |
45.9; 38.8; 51.3; 45.2; 37.6; 49.8 | — |
| SECONDARY Adverse Events |
0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Facial synkinesis
Exclusion Criteria
- Previous complication from botulinum toxin neuromodulator injection
- Inability to understand or complete the SAQ survey
- Inability to participate in follow-up
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT03048383) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.